- Advertisement -spot_img
HomeBusinessThird quarter: Shortly before the request for the vaccine: Biontech Pay shall

Third quarter: Shortly before the request for the vaccine: Biontech Pay shall

Third Quarter
Shortly before the request for the vaccine: Biontech Pay shall

The Mainz-based pharmaceutical company Biontech presents its Figures for the third quarter. Photo: Arne Dedert/dpa

© dpa-infocom GmbH

With a lot of messages that promise to his vaccine, Biontech has fueled great hopes in the fight against the Corona of a pandemic. Now, the Mainz-based company is informed of how it runs business.

Shortly after the release of encouraging interim results to his Corona vaccine, the Mainz-based pharmaceutical company Biontech today Figures for the third quarter.

In addition, Biontech will give at 14.00 in a conference call, “information for operational progress”. Biontech and the U.S. pharmaceutical company Pfizer had released on Monday as the first Western manufacturer with promising results for the pivotal vaccine trial. Your vaccine provide more than 90 percent protection against the disease Covid-19, said the two companies. Serious side effects had not been detected.

Biontech and Pfizer wish to apply for according to their own statements, it is likely that from next week the approval of US food and drug administration FDA. An effective Corona vaccine in Europe and the United States will be in reach. Federal Minister of health, Jens Spahn (CDU), said, he of a parallel application for the approval at the FDA and the European medicines Agency EMA.

Physicians were surprised by the research results of Biontech and Pfizer, financial analysts spoke of a possible breakthrough in the fight against the Corona of a pandemic. On the stock exchange, the shares of both companies shot up.

For Corona vaccines for urgency is because of the particular urgency, an accelerated approval process. In the case of the European medicines Agency EMA drug manufacturer can submit even before the complete application for approval of individual parts to the quality, safety and efficacy of a product. Such a procedure has been started in addition to Biontech, the British-Swedish company Astrazeneca for its vaccine candidate.

Biontech had developed the vaccine BNT162b2 in the project “Lightspeed” (speed of light) since the middle of January. For a pivotal Phase 3 study began from the end of July in different countries. By Monday, more than 43 500 people have gotten at least one of the two vaccinations to be administered at intervals of three weeks. A Vaccination is achieved, according to the manufacturer a week after the second injection.

Biontech and Pfizer expect this year worldwide, up to 50 million vaccine doses to provide in the coming year, you calculate with up to 1.3 billion cans. The EU Commission is already negotiating for some time with Biontech and Pfizer on a framework contract for the delivery of the vaccine to all EU member States.

dpa
Matthew Velterhttps://etrendystock.com/
With 5 years of experience as an editor, Matthew has been a crucial part of eTrendy Stock since its inception. He looks after the editing of news content published on eTrendy Stock. Apart from investing his time in editing, he also provides well-researched news articles for the U.S. niche. Mathew studied at University of central Florida.

Must Read

Related News